Your browser doesn't support javascript.
loading
Early myeloid-derived suppressor cells (HLA-DR-/lowCD33+CD16-) expanded by granulocyte colony-stimulating factor prevent acute graft-versus-host disease (GVHD) in humanized mouse and might contribute to lower GVHD in patients post allo-HSCT.
Wang, Ke; Lv, Meng; Chang, Ying-Jun; Zhao, Xiang-Yu; Zhao, Xiao-Su; Zhang, Yuan-Yuan; Sun, Yu-Qian; Wang, Zhi-Dong; Suo, Pan; Zhou, Yang; Liu, Dan; Zhai, Shu-Zhen; Hong, Yan; Wang, Yu; Zhang, Xiao-Hui; Xu, Lan-Ping; Liu, Kai-Yan; Huang, Xiao-Jun.
Afiliação
  • Wang K; Peking University People's Hospital, Peking University Institute of Hematology,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, No 11 Xizhimen South Street, Beijing, 100044, China.
  • Lv M; Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, No.5 Yiheyuan Road, Beijing, 100871, China.
  • Chang YJ; Peking University People's Hospital, Peking University Institute of Hematology,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, No 11 Xizhimen South Street, Beijing, 100044, China.
  • Zhao XY; Peking University People's Hospital, Peking University Institute of Hematology,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, No 11 Xizhimen South Street, Beijing, 100044, China.
  • Zhao XS; Peking University People's Hospital, Peking University Institute of Hematology,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, No 11 Xizhimen South Street, Beijing, 100044, China.
  • Zhang YY; Peking University People's Hospital, Peking University Institute of Hematology,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, No 11 Xizhimen South Street, Beijing, 100044, China.
  • Sun YQ; Peking University People's Hospital, Peking University Institute of Hematology,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, No 11 Xizhimen South Street, Beijing, 100044, China.
  • Wang ZD; Peking University People's Hospital, Peking University Institute of Hematology,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, No 11 Xizhimen South Street, Beijing, 100044, China.
  • Suo P; Peking University People's Hospital, Peking University Institute of Hematology,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, No 11 Xizhimen South Street, Beijing, 100044, China.
  • Zhou Y; Peking University People's Hospital, Peking University Institute of Hematology,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, No 11 Xizhimen South Street, Beijing, 100044, China.
  • Liu D; Peking University People's Hospital, Peking University Institute of Hematology,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, No 11 Xizhimen South Street, Beijing, 100044, China.
  • Zhai SZ; Peking University People's Hospital, Peking University Institute of Hematology,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, No 11 Xizhimen South Street, Beijing, 100044, China.
  • Hong Y; Peking University People's Hospital, Peking University Institute of Hematology,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, No 11 Xizhimen South Street, Beijing, 100044, China.
  • Wang Y; Peking University People's Hospital, Peking University Institute of Hematology,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, No 11 Xizhimen South Street, Beijing, 100044, China.
  • Zhang XH; Peking University People's Hospital, Peking University Institute of Hematology,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, No 11 Xizhimen South Street, Beijing, 100044, China.
  • Xu LP; Peking University People's Hospital, Peking University Institute of Hematology,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, No 11 Xizhimen South Street, Beijing, 100044, China.
  • Liu KY; Peking University People's Hospital, Peking University Institute of Hematology,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, No 11 Xizhimen South Street, Beijing, 100044, China.
  • Huang XJ; Peking University People's Hospital, Peking University Institute of Hematology,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, No 11 Xizhimen South Street, Beijing, 100044, China.
J Hematol Oncol ; 12(1): 31, 2019 03 18.
Article em En | MEDLINE | ID: mdl-30885244
ABSTRACT

INTRODUCTION:

Myeloid-derived suppressor cells (MDSCs) are proposed to control graft-versus-host disease (GVHD) in allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, the definition of human MDSCs has not yet reached consensus, and the mechanism of MDSCs to control GVHD remains unclear.

METHODS:

Immature myeloid cells (HLA-DR-/lowCD33+CD16-) were tested before and after granulocyte colony-stimulating factor (G-CSF) administration in healthy donor and isolated for suppression assays and co-culture with T cells in vitro. Isolated cells were infused in humanized mice for a xenogeneic model of acute GVHD. One hundred allo-HSCT recipients were enrolled prospectively to assess the role of HLA-DR-/lowCD33+CD16- cells in grafts on the occurrence of acute GVHD.

RESULTS:

In the present study, G-CSF mobilized HLA-DR-/lowCD33+CD16- cells with immunosuppressive properties in donor peripheral blood. These cells contained more interleukin-10+ and transforming growth factor-beta (TGF-ß)+ cells after G-CSF administration and inhibited the proliferation of autologous donor T cells in a TGF-ß-dependent manner. Meanwhile, these immature myeloid cells promoted regulatory T cell expansion and induced Th2 differentiation. Importantly, these cells prevented acute GVHD in a humanized mouse model. Moreover, clinical cohort results showed that the number of HLA-DR-/lowCD33+CD16- cells in the donor graft was the only independent risk factor inversely correlated with the incidence of grade II-IV acute GVHD in the recipients (HR 0.388, 95% CI 0.158-0.954, p = 0.039).

CONCLUSION:

HLA-DR-/lowCD33+CD16- cells represent functional MDSCs that may control acute GVHD in allo-HSCT.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante Homólogo / Fator Estimulador de Colônias de Granulócitos / Transplante de Células-Tronco Hematopoéticas / Condicionamento Pré-Transplante / Células Supressoras Mieloides / Doença Enxerto-Hospedeiro Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Animals Idioma: En Revista: J Hematol Oncol Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2019 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante Homólogo / Fator Estimulador de Colônias de Granulócitos / Transplante de Células-Tronco Hematopoéticas / Condicionamento Pré-Transplante / Células Supressoras Mieloides / Doença Enxerto-Hospedeiro Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Animals Idioma: En Revista: J Hematol Oncol Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2019 Tipo de documento: Article País de afiliação: China